Navigation Links
Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
Date:10/18/2011

NEW YORK, Oct. 18, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020

http://www.reportlinker.com/p0657236/Gardasil-Cervical-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020" provides Gardasil sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US and EU5

- Analysis and review of Gardasil including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Gardasil including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecasts for 2006-2020 for Gardasil in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 4

2.1 Cervical Cancer Vaccines Market 4

2.2 Epidemiology 4

2.3 Etiology 6

2.3.1 HPV Infections 6

2.3.2 Lack of Regular Papanicolaou (pap) Tests 7

2.3.3 Smoking 7

2.3.4 Sexual History 8

2.3.5 Birth Control Pills 8

2.4 GlobalData Report Guidance 8

3 Cervical Cancer Vaccines: Market Characterization 9

3.1 Cervical Cancer Vaccines Market 9

3.2 Drivers and Challenges for the Cervical Cancer Market 9

3.2.1 Drivers for Cervical Cancer Vaccine Market 9

3.2.2 Challenges for Cervical Cancer Vaccines 10

4 Gardasil (human papillomavirus vaccine(types6,11,16,18)) 11

4.1 Introduction 11

4.2 Human Papillomavirus Vaccine (HPV) 11

4.3 Mechanism of Action 11

4.4 Clinical Studies of Gardasil 11

4.4.1 Phase I and II trial 11

4.4.2 Phase III trial 12

4.5 Factors Affecting Sales 12

4.5.1 Cervical Cancer Market 12

4.5.2 Better Efficacy 13

4.5.3 Wide Disease Coverage 13

4.5.4 Public Health Advantage 13

4.5.5 Cost Effectiveness 13

4.5.6 Barriers to the Vaccination 13

4.6 Vaccine Evaluation 14

4.6.1 Efficacy 14

4.6.2 Safety 14

4.6.3 Dosing Convenience 15

4.6.4 Intensity of Competition 15

4.7 Sales forecast 16

4.7.1 Eligible population for Gardasil 16

4.7.2 Dosing 16

4.7.3 Market Penetration 16

4.7.4 Annual Cost of Therapy 17

4.7.5 Sales Projections of Gardasil 17

5 Cervical Cancer Vaccine Market: Appendix 24

5.1 Market Definitions 24

5.2 List of Abberiviations 24

5.3 Research Methodology 24

5.3.1 Coverage 25

5.3.2 Secondary Research 25

5.3.3 Forecasting 25

5.3.4 Population Approved to take Vaccine 26

5.3.5 Net Penetration of Vaccine 26

5.3.6 Net Annual Dosing 27

5.3.7 Annual Cost of Therapy 27

5.3.8 Primary Research 27

5.3.9 Expert Panels 27

5.4 Contact Us 27

5.5 Disclaimer 28

1.1 List of Tables

Table 1:Cervical Cancer, Estimated Incidences and Mortality, 2010-2020 5

Table 2: Estimated Prevalence of HPV in 9-26 years women 7

Table 3: Gardasil, Cervical Cancer Global, Sales Forecast ($m), 2006–2020 17

Table 4: Gardasil, Cervical Cancer, the US, Sales Forecast ($m), 2006–2020 18

Table 5: Gardasil, Cervical Cancer, UK, Sales Forecast ($m), 2006–2020 19

Table 6: Gardasil, Cervical Cancer, France, Sales Forecast ($m), 2006–2020 20

Table 7: Gardasil, Cervical Cancer, Germany, Sales Forecast ($m), 2006–2020 21

Table 8: Gardasil, Cervical Cancer, Italy, Sales Forecast ($m), 2006–2020 22

Table 9: Gardasil, Cervical Cancer, Spain, Sales Forecast ($m), 2006–2020 23

1.2 List of Figures

Figure 1: Estimated Prevalence of HPV in Women Aged between 9-26 Years in the US,EU-5 and Japan, 2010-2020 1

Figure 2: Distribution of Incidence and Mortality, Global, Top 26 Diagnosed Cancers,2010 4

Figure 3: Difference Between Percentage Distribution of Incidence and Mortality of Top 19 Cancers, 2008 6

Figure 4: Per Capita Cigarette Consumption, the US, 1976-2006 7

Figure 5: Efficacy comparison : Gardasil and Cervarix 14

Figure 6: Eligible population for Gardasil 16

Figure 7: Gardasil, Cervical Cancer Global, Sales Forecast ($m), 2006–2020 17

Figure 8: Gardasil, Cervical Cancer, the US, Sales Forecast ($m), 2006–2020 18

Figure 9: Gardasil, Cervical Cancer, UK, Sales Forecast ($m), 2006–2020 19

Figure 10: Gardasil, Cervical Cancer, France, Sales Forecast ($m), 2006–2020 20

Figure 11: Gardasil, Cervical Cancer, Germany, Sales Forecast ($m), 2006–2020 21

Figure 12: Gardasil, Cervical Cancer, Italy, Sales Forecast ($m), 2006–2020 22

Figure 13: Gardasil, Cervical Cancer, Spain, Sales Forecast ($m), 2006–2020 23

Figure 14: GlobalData Methodology 24

To order this report:

Pathology Industry: Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020

Pathology Business News

More  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA: Gardasil Approved to Prevent Anal Cancer
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
7. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
8. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
11. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 ... perampanel presented at the 2016 Annual Meeting of the ... as FYCOMPA® CIII, is indicated as an adjunctive therapy ... or without secondarily generalized seizures and primary generalized tonic-clonic ... years of age and older. Please see Important Safety ...
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, LLC ... Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February 24, ... honored to have Amy E. Herman present at this year’s conference, her unprecedented ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson who has ... Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , The sessions ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... way to ensure moisture measurements are consistently correct. However, regular performance testing ... Now, METTLER TOLEDO offers a solution: SmartCal™ . This innovative test ...
Breaking Medicine News(10 mins):